Literature DB >> 18177454

Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging.

Ji Y Kim1, Myung-Hwan Kim, Tae Y Lee, Chang Y Hwang, Jae S Kim, Sung-Cheol Yun, Sang S Lee, Dong W Seo, Sung K Lee.   

Abstract

OBJECTIVES: This study was conducted to evaluate the clinical role of integrated positron emission and computed tomography (PET-CT) in patients with suspected and potentially operable cholangiocarcinoma.
METHODS: Between October 2005 and May 2007, 123 patients with suspected cholangiocarcinoma were enrolled in this study after diagnostic workup, including biliary dynamic computed tomography (CT) and magnetic resonance imaging/magnetic resonance cholangiopancreatography (MRI/MRCP) with magnetic resonance (MR) angiography. Patients with overt unresectable cholangiocarcinoma or gallbladder cancer diagnosed via conventional imaging were excluded. Consecutively, each enrolled patient underwent PET-CT. Data were prospectively collected and analyzed in comparison with CT and MRI/MRCP.
RESULTS: The overall values for sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of PET-CT in primary tumor detection were 84.0%, 79.3%, 92.9%, 60.5%, and 82.9%, respectively. PET-CT demonstrated no statistically significant advantage over CT and MRI/MRCP in the diagnosis of primary tumor. According to different morphologic characteristics of cholangiocarcinoma, PET-CT showed no significant difference in detecting those of mass-forming, periductal-infiltrating, and intraductal-growing types. PET-CT revealed significantly higher accuracy over CT in the diagnosis of regional lymph nodes metastases (75.9%vs 60.9%, P= 0.004) and distant metastases (88.3%vs 78.7%, P= 0.004). Additional use of PET-CT for assessing resectability correctly showed different results from those determined by conventional imaging in 15 (15.9%) of 94 patients with cholangiocarcinoma.
CONCLUSIONS: PET-CT improved the accuracy of preoperative staging in patients with cholangiocarcinoma planning to undergo curative resection. Thus, PET-CT had an important clinical impact on the selection of proper treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18177454     DOI: 10.1111/j.1572-0241.2007.01710.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  51 in total

Review 1.  Imaging and interventions in hilar cholangiocarcinoma: A review.

Authors:  Kumble Seetharama Madhusudhan; Shivanand Gamanagatti; Arun Kumar Gupta
Journal:  World J Radiol       Date:  2015-02-28

2.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

3.  Preoperative Risk Score to Predict Occult Metastatic or Locally Advanced Disease in Patients with Resectable Perihilar Cholangiocarcinoma on Imaging.

Authors:  Jimme K Wiggers; Bas Groot Koerkamp; David van Klaveren; Robert J Coelen; C Yung Nio; Peter J Allen; Marc G Besselink; Olivier R Busch; Michael I D'Angelica; Ronald P DeMatteo; T Peter Kingham; Thomas M van Gulik; William R Jarnagin
Journal:  J Am Coll Surg       Date:  2018-04-06       Impact factor: 6.113

Review 4.  Imaging of Cholangiocarcinoma.

Authors:  Susann-Cathrin Olthof; Ahmed Othman; Stephan Clasen; Christina Schraml; Konstantin Nikolaou; Malte Bongers
Journal:  Visc Med       Date:  2016-12-06

5.  A case of intrahepatic cholangiocarcinoma detected after successful interferon therapy for chronic hepatitis C.

Authors:  Hiroji Shinkawa; Seikan Hai; Hiromu Tanaka; Shigekazu Takemura; Kazuki Ohba; Takahiro Uenishi; Shintaro Kodai; Yorihisa Urata; Kazuhisa Kaneda; Masayuki Sakae; Kenichi Wakasa; Shoji Kubo
Journal:  Clin J Gastroenterol       Date:  2009-12-03

Review 6.  Perihilar cholangiocarcinoma: a surgeon's viewpoint on current topics.

Authors:  Masato Nagino
Journal:  J Gastroenterol       Date:  2012-07-31       Impact factor: 7.527

Review 7.  Surgical outcomes of intrahepatic cholangiocarcinoma.

Authors:  Masakazu Yamamoto; Shun-ichi Ariizumi
Journal:  Surg Today       Date:  2011-07-12       Impact factor: 2.549

Review 8.  The treatment of cholangiocarcinoma: a hepatologist's perspective.

Authors:  Kamran Qureshi; Randhir Jesudoss; Abdullah M S Al-Osaimi
Journal:  Curr Gastroenterol Rep       Date:  2014-10

9.  Late recurrence after resection of mass-forming intrahepatic cholangiocarcinoma: report of a case.

Authors:  Naoko Iwahashi Kondo; Ken Shirabe; Yohei Mano; Akinobu Taketomi; Tomoharu Yoshizumi; Toru Ikegami; Toshiro Masuda; Hiroto Kayashima; Naotaka Hashimoto; Kazutoyo Morita; Mizue Matsuo; Yoshihiko Maehara
Journal:  Surg Today       Date:  2012-09-14       Impact factor: 2.549

10.  Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer.

Authors:  Ka Wing Ma; Tan To Cheung; Wong Hoi She; Kenneth Siu Ho Chok; Albert Chi Yan Chan; Wing Chiu Dai; Wan Hang Chiu; Chung Mau Lo
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.